DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice

Vaccine

Volumn 21, Issue 3-4, 2002, Pages 247-257

  Lopez Fuertes L ^a   Perez Jimenez E ^b   Vila Coro, A J ^a   Sack, F ^c   Moreno, S ^a   Konig, S A ^a   Junghans, C ^c   Wittig, B ^c,d   Timon M ^a   Esteban, M ^b  

^a Mologen Molecular Medicines SL   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c MOLOGEN AG   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

DNA vaccine; Leishmania; MIDGE; MIDGE, minimalistic, linear expression vectors; NLS, nuclear localization signal

Indexed keywords

DNA VACCINE; NUCLEAR LOCALIZATION SIGNAL PEPTIDE; PEPTIDE; PLASMID DNA; PLASMID VECTOR; UNCLASSIFIED DRUG; LACK ANTIGEN, LEISHMANIA; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA VECTOR; FEMALE; GENE EXPRESSION; GENE SEQUENCE; IMMUNE RESPONSE; INFECTION PREVENTION; LEISHMANIA MAJOR; LEISHMANIASIS; MINIMALISTIC IMMUNOGENICALLY DEFINED GENE EXPRESSION VECTOR; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL CULTURE; GENE VECTOR; GENETICS; HELA CELL; HUMAN; IMMUNIZATION; IMMUNOLOGY; SKIN LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; GENE EXPRESSION; GENETIC VECTORS; HELA CELLS; HUMANS; IMMUNIZATION; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0037073555     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00450-4     Document Type: Article

References (40)

1. World Health Organization, WHO. Technical Report Series, No. 793, 1990.
2. Bettini S., Gradoni L. Canine leishmaniasis in the Mediterranean area and its implications for human leishmaniasis. Insect. Sci. Appl. 7:1986;241-245.
3. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:1995;151.
4. Mattner F., Magram J., Ferrante J.et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1996;1553-1559.
5. Heinzel F.P., Sadick M.D., Mutha S.S., Locksley R.M. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. U.S.A. 88(16):1991;7011-7015.
6. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis T cell lines that transfer protective immunity and exacerbation belongs to different T helper subsets and response to distinct parasite antigens. J. Exp. Med. 168:1988;1675-1684.
7. Sher A., Coffman R.L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Ann. Rev. Immunol. 10:1992;385-409.
8. Xu D., Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine. 12:1994;1534-1536.
9. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against L. amazonensis infection. Infect. Immunol. 56:1988;3272-3279.
10. Soong L., Duboise S.M., Kima P., McMahon-Pratt D. Leishmania pifanoi amastigote antigens protects mice against cutaneous leishmaniasis. Infect. Immunol. 63:1995;3556-3559.
11. González-Aseguinolaza G., Taladriz S., Marquet A., Larraga V. Molecular cloning. Eur. J. Biochem. 259:1999;909-916.
12. Maillard I., Launois P., Himmelrich H.et al. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Eur. J. Immunol. 31(4):2001;1288-1296.
13. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchier G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 263(5144):1994;235-237.
14. Mougneau E., Altare F., Wakil A.E.et al. Expression cloning of a protective Leishmania antigen. Science. 268(5210):1995;563-566.
15. Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274(5286):1996;421-423.
16. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
17. Tighe H., Corr M., Roman M., Raz M. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today. 19(2):1998;89-97.
18. Moss B. Genetically engineered poxviruses for recombinant gene expression. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11341-11348.
19. Paoletti E. Applications of poxvirus vectors to vaccination: an update. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11349-11353.
20. Rodríguez D., Rodriguez J.R., Llorente M.et al. Use of DNA priming and vaccinia virus boosting to trigger an efficient immune response to HIV-1 gp120. Gene Therapy Mol. Biol. 3:1999;179-187.
21. + T cells. Virology. 280:2001;155-159.
22. McMahon-Pratt D., Rodriguez D., Rodriguez J.R.et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmaniainfection. Infect. Immunol. 61(8):1993;3351-3359.
23. Gonzalo R.M., del Real G., Rodriguez J.R. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine. 20(7/8):2002;1226-1231.
24. Schirmbeck R., Konig-Merediz S.A., Riedl P.et al. Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. J. Mol. Med. 79(5/6):2001;343-350.
25. Branden L.J., Mohamed A.J., Smith C.I. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat. Biotechnol. 17(8):1999;784-787.
26. Ludtke J.J., Zhang G., Sebestyen M.G., Wolff J.A. A nuclear localization signal can enhance both the nuclear transport and expression of 1 kb DNA. J. Cell. Sci. 112( Pt 12):1999;2033-2041.
27. Zanta M.A., Belguise-Valladier P., Behr J.P. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc. Natl. Acad. Sci. U.S.A. 96(1):1999;91-96.
28. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:1995;3403-3409.
29. Mougneau E., Altare F., Wakil A.E. Expression cloning of a protective Leishmania antigen. Science. 268(5210):1995;563-566.
30. Caver T.E., Lockey T.D., Srinivas R.V., Webster R.G., Hurwitz J.L. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine. 17:1999;1567-1572.
31. Hanke T., Blanchard T.J., Schneider J.et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regimen. Vaccine. 16:1998;439-445.
32. Hanke T., McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 66:1999;177-181.
33. Hanke T., Samuel R.V., Blanchard T.J.et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitotic gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532.
34. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:1998;10180-10188.
35. Robinson H.L., Montefiori D., Johnson P.et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant Pox virus booster immunizations. Nat. Med. 5:1999;526-534.
36. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A.et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7648-7653.
37. Cressman D.E., O'Connor W.J., Greer S.F., Zhu X.S., Ting J.P. Mechanisms of nuclear import and export that control the subcellular localization of class II transactivator. J. Immunol. 167(7):2001;3626-3634.
38. Schneider J., Langermans J.A., Gilbert S.C.et al. A prime-boost immunisation regimen using DNA followed by recombinant-modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine. 19(32):2001;4595-4602.
39. Gherardi M.M., Ramirez J.C., Esteban M. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol. Histopathol. 16(2):2001;655-667.
40. Schneider J., Gilbert S.C.et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170:1999;29-38.